NCT07443371

Brief Summary

The objective of the present study is to explore the effect of Transfer Energy Capacitive and Resistive Therapy (TECAR) therapy on pain, range of motion (ROM) and hand function in dupuytren's contracture patients (palmar fibromatosis).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 25, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 2, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

March 2, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2026

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2026

Completed
Last Updated

March 2, 2026

Status Verified

February 1, 2026

Enrollment Period

2 months

First QC Date

February 25, 2026

Last Update Submit

February 25, 2026

Conditions

Palmar Fibromatosis

Outcome Measures

Primary Outcomes (3)

  • Active range of motion (ROM) assessment of metacarpophalangeal joint (MCP):

    * Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her. * The therapist will stabilize the metacarpal bone. * The goniometer axis will be placed over the dorsal surface of the MCP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the metacarpal bone and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx. * The patient will be asked to flex then extend his MCP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion (ROM) will be documented.

    6 weeks

  • Active range of motion (ROM) assessment of proximal interphalangeal joint (PIP):

    * Patient Position: Sitting on a chair while his/her forearm will be in a mid position and supported with the involved hand on the plinth beside him/her. * The therapist will stabilize the proximal phalanx. * The goniometer axis will be placed over the dorsal surface of the PIP joint. The stationary arm of the goniometer will be placed parallel to the longitudinal axis of the proximal phalanx and the movable arm of the goniometer will be placed parallel to the longitudinal axis of the middle phalanx. * The patient will be asked to flex then extend his PIP joint to the limit of the motion (normally 0º-100º extension-flexion) then range of motion ROM will be documented.

    6 weeks

  • Pain intensity measurement

    The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'pain as bad as it could be'. The patient is asked to mark his pain level on the line between the two endpoints. The distance between 'no pain at all' and the mark then defines the subject's pain From 0 to 10 , (0 )means no pain and up to (10) means intolerable pain

    6 weeks

Secondary Outcomes (1)

  • The Southampton Dupuytren's Scoring Scale

    6 weeks

Study Arms (2)

Transfer Energy Capacitive and Resistive (TECAR) therapy

EXPERIMENTAL

The patients will receive Tecar therapy, in addition to traditional therapy for 6 weeks

Device: Transfer Energy Capacitive and Resistive (TECAR) therapyOther: Traditional therapy

Traditional therapy group

ACTIVE COMPARATOR

The patients will receive traditional therapy only for 6 weeks .

Other: Traditional therapy

Interventions

Transfer Energy Capacitive and Resistive (TECAR) therapyDEVICE

The apparatus used is comprised of a generator that supplies a signal at the frequency of 0.5 MHz and a maximum power of 300 watts (HCR900).The power can be regulated by controlling the quantity of transferred energy and the relative biological action. The counter electrode (Return Plate) that closes the circuit consists of a metal plate that is applied in opposition or a cylinder that is clasped. The head of the device will be applied over the treated area for 20 minutes (min) (10 min of capacitive head and 10 min of resistive head), moderate to high intensity. It will be applied along and in circles over the affected palm, 3 sessions weekly for 6 weeks.

Transfer Energy Capacitive and Resistive (TECAR) therapy
Traditional therapyOTHER

The patients will receive the traditional physical therapy program 3 sessions / week , for 6 weeks totally. It consists of stretching exercise, flexor tendon glide and splinting.

Traditional therapy groupTransfer Energy Capacitive and Resistive (TECAR) therapy

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages of patients will be ranged from 40 to 70 years.
  • Presence of palpable cords and/or digital contracture ≥ 20° at the metacarpophalengeal joint or Proximal interphalengeal joint joints .
  • Clinical diagnosis confirmed by a hand surgeon or relevant specialist.
  • All patients will enter the study having their informed consent

You may not qualify if:

  • Patient with severe contracture \>30° or multiple digit involvement requiring surger.
  • History of surgical release (fasciotomy, fasciectomy) or collagenase injection in the affected hand.
  • Presence of infection, ulceration, or skin lesions on the treatment area.
  • Presence of pacemakers, metal implants, or other electronic implants in the treatment area.
  • Active cancer or tumor in the treatment region.
  • Pregnancy.
  • Conditions such as stroke, Parkinson's disease, or rheumatoid arthritis that may confound results.
  • Cognitive impairment, psychiatric illness, or other barriers to protocol adherence

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peter Milad Haroun

Cairo, Egypt

Location

MeSH Terms

Conditions

Dupuytren Contracture

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

FibromaNeoplasms, Fibrous TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsContractureMuscular DiseasesMusculoskeletal DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Amir Zaki, PHD

    Cairo University

    STUDY DIRECTOR

  • Hussein Mogahed, Professor

    Cairo University

    STUDY CHAIR

Central Study Contacts

Peter Haroun, Master

CONTACT

01289951508DpTpeter2019@gmail.com

Ahmed Zarraa, PHD

CONTACT

01007580084dptahmedzarraa91@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

February 25, 2026

First Posted

March 2, 2026

Study Start

March 2, 2026

Primary Completion

May 15, 2026

Study Completion

May 30, 2026

Last Updated

March 2, 2026

Record last verified: 2026-02

Locations

EG(1)